BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Optasia Medical Limited Joins the National Bone Health Alliance (NBHA)


5/31/2011 10:54:10 AM

MANCHESTER, UNITED KINGDOM and SUDBURY, MA--(Marketwire - May 31, 2011) - Optasia Medical Inc., a leading provider of imaging productivity tools, today announced that it has joined the National Bone Health Alliance (NBHA). Optasia Medical's premier product, SpineAnalyzer™, is an innovative workflow tool for the quantitative assessment of vertebral deformities in patients at risk of osteoporotic fractures. The output of the device may be used by physicians to assist in the diagnosis of vertebral fractures, a key factor to determine if therapeutic intervention is indicated.

The ability to accurately assess vertebral fractures is rapidly gaining an increased role in clinical practice. The National Osteoporosis Foundation's "Clinician's Guide to Prevention and Treatment of Osteoporosis" states that patients with a clinical or morphometric vertebral fracture should be considered for treatment even in cases when their bone density is not at a level considered osteoporotic. In addition, the Guide recommends using the World Health Organization's Fracture Risk Assessment Tool (FRAX) to estimate a patient's 10-year fracture risk, where previous fractures, including vertebral fractures, have a significant impact on a patient's risk.

Established in 2010, the National Bone Health Alliance (NBHA) is a public-private partnership that brings together the expertise and resources of various partners across a broad spectrum to promote bone health and prevent disease; improve diagnosis and treatment of bone disease; and enhance bone research, surveillance and evaluation. Founding members include the American Academy of Orthopedic Surgeons, American Society for Bone and Mineral Research, Health Monitor Network, National Osteoporosis Foundation, the Paget Foundation for Paget's Disease of Bone and Related Disorders and the Osteogenesis Imperfecta Foundation. For more information on the NBHA, visit www.nbha.org.

"Optasia Medical is very pleased to have joined twenty-two other leading healthcare organizations and providers in support of the initiatives of the NBHA," said Jim DePass, Optasia Medical's Vice President of Business Development for the US. "In 2005, over 2 million osteoporosis-related fractures occurred in the US, a number expected to reach 3 million by 2025. The costs related to these fractures were $16.9 billion in 2005 and are predicted to rise to $25 billion by 2025. Despite the availability of bone densitometry and pharmacological therapies, the incidence and costs related to osteoporosis have not decreased. What we sorely need to reduce these costs is more public awareness of osteoporosis in combination with better tools for diagnosis and treatment and that is the goal of the NBHA."

About Optasia Medical
Optasia Medical Inc. develops novel imaging productivity tools that automate the process of viewing, analysis and interpretation of musculoskeletal x-rays. Using these tools, physicians are able to make a more accurate diagnosis, provide meaningful monitoring of patients to determine if therapy is effective and help motivate patients to improve their compliance. Optasia Medical's products currently address three major musculoskeletal diseases -- osteoporosis, rheumatoid arthritis and osteoarthritis -- diseases that impact a very large number of patients due to the aging population and result in billions of dollars spent on therapy.

For additional information on Optasia Medical and SpineAnalyzer, please visit www.optasiamedical.com


Contact:
James DePass
Vice-President, Business Development
Optasia Medical Inc.
Tel: +1 (608) 469-6259
e-mail: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES